190 related articles for article (PubMed ID: 20802826)
1. The combination of rifampin plus moxifloxacin is synergistic for suppression of resistance but antagonistic for cell kill of Mycobacterium tuberculosis as determined in a hollow-fiber infection model.
Drusano GL; Sgambati N; Eichas A; Brown DL; Kulawy R; Louie A
mBio; 2010 Aug; 1(3):. PubMed ID: 20802826
[TBL] [Abstract][Full Text] [Related]
2. Effect of administration of moxifloxacin plus rifampin against Mycobacterium tuberculosis for 7 of 7 days versus 5 of 7 days in an in vitro pharmacodynamic system.
Drusano GL; Sgambati N; Eichas A; Brown D; Kulawy R; Louie A
mBio; 2011; 2(4):e00108-11. PubMed ID: 21750119
[TBL] [Abstract][Full Text] [Related]
3. In vitro postantibiotic effects of rifapentine, isoniazid, and moxifloxacin against Mycobacterium tuberculosis.
Chan CY; Au-Yeang C; Yew WW; Leung CC; Cheng AF
Antimicrob Agents Chemother; 2004 Jan; 48(1):340-3. PubMed ID: 14693563
[TBL] [Abstract][Full Text] [Related]
4. Activity of Moxifloxacin against
Louie A; Duncanson B; Myrick J; Maynard M; Nole J; Brown D; Schmidt S; Neely M; Scanga CA; Peloquin C; Drusano GL
Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30249693
[TBL] [Abstract][Full Text] [Related]
5. Moxifloxacin and gatifloxacin in an acid model of persistent Mycobacterium tuberculosis.
Kubendiran G; Paramasivan CN; Sulochana S; Mitchison DA
J Chemother; 2006 Dec; 18(6):617-23. PubMed ID: 17267339
[TBL] [Abstract][Full Text] [Related]
6. Bactericidal activity of moxifloxacin on exponential and stationary phase cultures of Mycobacterium tuberculosis.
Sulochana S; Mitchison DA; Kubendiren G; Venkatesan P; Paramasivan CN
J Chemother; 2009 Apr; 21(2):127-34. PubMed ID: 19423464
[TBL] [Abstract][Full Text] [Related]
7. Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling.
Gumbo T; Louie A; Deziel MR; Parsons LM; Salfinger M; Drusano GL
J Infect Dis; 2004 Nov; 190(9):1642-51. PubMed ID: 15478070
[TBL] [Abstract][Full Text] [Related]
8. Effect of coadministration of moxifloxacin and rifampin on Mycobacterium tuberculosis in a murine aerosol infection model.
Balasubramanian V; Solapure S; Gaonkar S; Mahesh Kumar KN; Shandil RK; Deshpande A; Kumar N; Vishwas KG; Panduga V; Reddy J; Ganguly S; Louie A; Drusano GL
Antimicrob Agents Chemother; 2012 Jun; 56(6):3054-7. PubMed ID: 22470118
[TBL] [Abstract][Full Text] [Related]
9. Impact of fluoroquinolone resistance on bactericidal and sterilizing activity of a moxifloxacin-containing regimen in murine tuberculosis.
Fillion A; Aubry A; Brossier F; Chauffour A; Jarlier V; Veziris N
Antimicrob Agents Chemother; 2013 Sep; 57(9):4496-500. PubMed ID: 23836169
[TBL] [Abstract][Full Text] [Related]
10. In vitro combination studies of benzothiazinone lead compound BTZ043 against Mycobacterium tuberculosis.
Lechartier B; Hartkoorn RC; Cole ST
Antimicrob Agents Chemother; 2012 Nov; 56(11):5790-3. PubMed ID: 22926573
[TBL] [Abstract][Full Text] [Related]
11. Minimising moxifloxacin resistance with tuberculosis.
Drlica K; Zhao X; Kreiswirth B
Lancet Infect Dis; 2008 May; 8(5):273-5. PubMed ID: 18471768
[No Abstract] [Full Text] [Related]
12. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model.
Rosenthal IM; Zhang M; Williams KN; Peloquin CA; Tyagi S; Vernon AA; Bishai WR; Chaisson RE; Grosset JH; Nuermberger EL
PLoS Med; 2007 Dec; 4(12):e344. PubMed ID: 18092886
[TBL] [Abstract][Full Text] [Related]
13. A Faropenem, Linezolid, and Moxifloxacin Regimen for Both Drug-Susceptible and Multidrug-Resistant Tuberculosis in Children: FLAME Path on the Milky Way.
Deshpande D; Srivastava S; Nuermberger E; Pasipanodya JG; Swaminathan S; Gumbo T
Clin Infect Dis; 2016 Nov; 63(suppl 3):S95-S101. PubMed ID: 27742640
[TBL] [Abstract][Full Text] [Related]
14. Effect of Moxifloxacin plus Pretomanid against
de Miranda Silva C; Hajihosseini A; Myrick J; Nole J; Louie A; Schmidt S; Drusano GL
Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30397058
[TBL] [Abstract][Full Text] [Related]
15. Concentration-Dependent Synergy and Antagonism of Linezolid and Moxifloxacin in the Treatment of Childhood Tuberculosis: The Dynamic Duo.
Deshpande D; Srivastava S; Nuermberger E; Pasipanodya JG; Swaminathan S; Gumbo T
Clin Infect Dis; 2016 Nov; 63(suppl 3):S88-S94. PubMed ID: 27742639
[TBL] [Abstract][Full Text] [Related]
16. In vivo validation of the mutant selection window hypothesis with moxifloxacin in a murine model of tuberculosis.
Almeida D; Nuermberger E; Tyagi S; Bishai WR; Grosset J
Antimicrob Agents Chemother; 2007 Dec; 51(12):4261-6. PubMed ID: 17938193
[TBL] [Abstract][Full Text] [Related]
17. Analysis of combination drug therapy to develop regimens with shortened duration of treatment for tuberculosis.
Drusano GL; Neely M; Van Guilder M; Schumitzky A; Brown D; Fikes S; Peloquin C; Louie A
PLoS One; 2014; 9(7):e101311. PubMed ID: 25003557
[TBL] [Abstract][Full Text] [Related]
18. Dose optimization of moxifloxacin and linezolid against tuberculosis using mathematical modeling and simulation.
Heinrichs MT; Drusano GL; Brown DL; Maynard MS; Sy SKB; Rand KH; Peloquin CA; Louie A; Derendorf H
Int J Antimicrob Agents; 2019 Mar; 53(3):275-283. PubMed ID: 30385322
[TBL] [Abstract][Full Text] [Related]
19. Moxifloxacin lethality against Mycobacterium tuberculosis in the presence and absence of chloramphenicol.
Malik M; Drlica K
Antimicrob Agents Chemother; 2006 Aug; 50(8):2842-4. PubMed ID: 16870782
[TBL] [Abstract][Full Text] [Related]
20. Rifapentine, moxifloxacin, or DNA vaccine improves treatment of latent tuberculosis in a mouse model.
Nuermberger E; Tyagi S; Williams KN; Rosenthal I; Bishai WR; Grosset JH
Am J Respir Crit Care Med; 2005 Dec; 172(11):1452-6. PubMed ID: 16151038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
